本文選題：Arid1a + BAF250a��； 參考：《皖南醫(yī)學(xué)院》2017年碩士論文

【摘要】：目的:研究Arid1a蛋白表達(dá)情況與胃癌發(fā)病及其腫瘤病理特征之間的關(guān)系。方法:選取皖南醫(yī)學(xué)院第一附屬弋磯山醫(yī)院2012年至2015年之間行胃癌根治術(shù)以及胃良性病變大部切除術(shù)的患者,排除胃原位癌及遠(yuǎn)處器官轉(zhuǎn)移患者。對(duì)胃癌標(biāo)本(含癌旁組織)以及正常胃粘膜的組織蠟塊切片后進(jìn)行免疫組化染色(一抗為兔抗人單克隆Arid1a抗體,克隆號(hào)EPR13501)。在兩位病理醫(yī)師指導(dǎo)下對(duì)每張切片進(jìn)行結(jié)果判定。收集患者的一般資料、既往病史以及腫瘤病理特征等資料;最后運(yùn)用統(tǒng)計(jì)學(xué)方法對(duì)結(jié)果進(jìn)行分析。結(jié)果:本次研究共完成正常胃黏膜免疫組化染色42例以及胃癌組織免疫組化染色104例,其中包含癌旁組織的免疫組化染色切片75例。Arid1a蛋白在正常胃黏膜、癌旁組織以及胃癌組織中的表達(dá)缺失率分別4.76%(2/42)、8.00%(6/75)、23.08%(24/104);Arid1a蛋白在胃癌組織中表達(dá)缺失率最高,且差異存在統(tǒng)計(jì)學(xué)意義(正常胃黏膜vs胃癌組織,P=0.008;癌旁組織vs胃癌組織,P=0.008)。Arid1a蛋白在胃癌患者中的表達(dá)缺失率與性別、年齡、是否吸煙以及飲酒之間均無明顯相關(guān)性(均P0.05)。但與既往有胃潰瘍病史有關(guān),且差異有統(tǒng)計(jì)學(xué)意義(P=0.048)。通過分析發(fā)現(xiàn),Arid1a蛋白表達(dá)缺失率與腫瘤位置,Lauren分型,分化程度以及是否有神經(jīng)侵犯之間無相關(guān)性(均P0.05)。在腫瘤浸潤深度方面,實(shí)驗(yàn)結(jié)果顯示T3+T4期胃癌病例占63.46%(66/104);腫瘤浸潤越深(T分期),其Arid1a蛋白表達(dá)缺失率越高。Arid1a蛋白表達(dá)缺失率在T3、T4期胃癌患者中分別為30.00%(9/30)、33.33%(12/36);明顯高于T1期(6.67%,1/15)及T2期(8.70%,2/23),差別存在統(tǒng)計(jì)學(xué)意義(P=0.048)。同時(shí)發(fā)現(xiàn)淋巴結(jié)轉(zhuǎn)移越多,胃癌組織中Arid1a蛋白表達(dá)缺失率也越高,其中N2、N3胃癌組織中Arid1a蛋白表達(dá)缺失率分別為31.82%(7/22)和41.38%(12/29),明顯高于N0(6.90%)及N1(12.50%)的Arid1a蛋白表達(dá)缺失率,且差別存在統(tǒng)計(jì)學(xué)意義(P=0.007)。在伴有脈管侵犯的胃癌患者中,其Arid1a蛋白表達(dá)缺失率明顯高于無脈管侵犯的胃癌患者,差別有統(tǒng)計(jì)學(xué)意義(37.50%vs14.06%,P=0.008)。腫瘤直徑大于5cm的胃癌患者中Arid1a蛋白表達(dá)缺失率最高,達(dá)42.42%(13/41),明顯高于腫瘤小于等于3cm(5.88%)和大于3小于等于5cm(21.62%)的胃癌患者,差別有統(tǒng)計(jì)學(xué)意義(P=0.002)。結(jié)論:既往有胃潰瘍病史的胃癌患者Arid1a蛋白表達(dá)缺失率高,提示Arid1a蛋白表達(dá)缺失與胃潰瘍有關(guān)。Arid1a蛋白表達(dá)缺失與胃癌腫瘤大小、浸潤深度、淋巴結(jié)轉(zhuǎn)移及脈管侵犯等腫瘤特征有關(guān);提示Arid1a蛋白表達(dá)缺失的胃癌患者具有較差的腫瘤生物學(xué)行為。Arid1a蛋白表達(dá)缺失與胃癌的發(fā)病有關(guān),提示Arid1a基因可能是一種抑癌基因。
[Abstract]:Objective: to study the relationship between the expression of Arid1a protein and the pathogenesis and pathological features of gastric cancer. Methods: patients who underwent radical gastrectomy and subtotal resection of benign gastric lesions between 2012 and 2015 were selected to exclude patients with gastric carcinoma in situ and distant organ metastasis. The specimens of gastric cancer (including paracancerous tissue) and normal gastric mucosa were stained with immunohistochemical staining (rabbit monoclonal Arid1a antibody, clone EPR13501). The results of each section were determined under the guidance of two pathologists. Collect the general data of the patients, past medical history and tumor pathological characteristics. Finally, the results were analyzed by statistical method. Results: in this study, 42 cases of normal gastric mucosa and 104 cases of gastric cancer tissues were stained with immunohistochemical staining, including 75 cases of immunohistochemical sections of paracancerous tissues. Arid1a protein was found in normal gastric mucosa. The deletion rate of Arid1a protein in paracancerous tissues and gastric cancer tissues was 4.76% (2 / 42) and 8.00% (6 / 75) or 23.08% (24 / 104), respectively. There was no significant correlation between the deletion rate of Arid1a protein and sex, age, smoking or alcohol consumption in gastric cancer patients (normal gastric mucosa vs gastric cancer tissue P0. 008; paracancerous tissue vs gastric cancer tissue P0. 008). But it was related to the history of gastric ulcer, and the difference was statistically significant (P0. 048). It was found that there was no correlation between the deletion rate of Arid1a protein and the Lauren type of tumor location, the degree of differentiation and the presence of neural invasion (P0.05). In terms of the depth of tumor infiltration, The results showed that 63.46% (66 / 104) of patients with T3T4 gastric cancer, and 63.46% (66 / 104) of patients with T3T4 gastric cancer, the higher the loss rate of Arid1a protein expression was, the higher the deletion rate of Arid1a protein expression was in T3T4 stage gastric cancer patients (30.00% (9/ 30) 33.33% (12 / 36), respectively), which was significantly higher than that in T1 stage (6.67115) and T2 stage (8.70% / 23). The difference was statistically significant (P0. 048). It was also found that the higher the lymph node metastasis, the higher the deletion rate of Arid1a protein in gastric cancer tissue. The deletion rate of Arid1a protein in N2N3 gastric cancer was 31.82% (7 / 22) and 41.38% (12 / 29) respectively, which was significantly higher than that of N0 (6.90%) and N1 (12.50%). The difference was statistically significant (P0. 007). The loss rate of Arid1a protein expression in patients with vascular invasion was significantly higher than that in patients without vessel invasion (37.50 vs 14.06). The deletion rate of Arid1a protein in patients with tumor diameter larger than 5cm was 42.42% (13 / 41), which was significantly higher than that in patients with tumor less than or equal to 3cm (5.88%) and greater than 3 (less than 3 equal to 5cm (21.62%) (P < 0.002). Conclusion: the deletion rate of Arid1a protein in gastric cancer patients with a history of gastric ulcer is high, suggesting that the loss of Arid1a protein expression is related to gastric ulcer and the tumor size and depth of invasion. Lymph node metastasis and vascular invasion were related to the tumor characteristics, suggesting that the loss of Arid1a protein expression in gastric cancer patients had poor tumor biological behavior. The loss of Arid1a protein expression was associated with the pathogenesis of gastric cancer, suggesting that the Arid1a gene might be a tumor suppressor gene.
【學(xué)位授予單位】：皖南醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 Suk-young Lee;Sang Cheul Oh;;Changing strategies for target therapy in gastric cancer[J];World Journal of Gastroenterology;2016年03期

2 Wanqing Chen;Rongshou Zheng;Hongmei Zeng;Siwei Zhang;Jie He;;Annual report on status of cancer in China, 2011[J];Chinese Journal of Cancer Research;2015年01期

3 Jie Chen;Su-Jun Zhou;Yun Zhang;Guo-Qiang Zhang;Tian-Zhou Zha;Yi-Zhong Feng;Kai Zhang;;Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer[J];World Journal of Gastroenterology;2013年13期

，

本文編號(hào)：2058646